All In Biotech

Drug Trial Radar · NCT06849973

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Phase 2/ Phase 3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Mar 15, 2024

Primary completion

Nov 22, 2024

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Biomed Industries, Inc.Industry
Sponsor type
Industry
First posted
Feb 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 5 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the efficacy \& safety of oral Bionetide versus placebo in girls and women with Rett syndrome

Conditions

  • Rett Syndrome

Interventions

  • Drug: BionetideDrug

    NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

  • PlaceboDrug

    NA-921 (Bionetide) placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12Time frame: Baseline and Week 12
  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12Time frame: 12 Weeks Treatment Duration

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Biomed Testing Facility # BIO-04-92093

    La Jolla, California

  • Biomed Testing Facility # BIO-03-90095

    Los Angeles, California

  • Biomed Testing Facility # BIO-02-95817

    Sacramento, California

  • Biomed Testing Facility # BIO-01-94104

    San Francisco, California

  • Biomed Testing Facility #BIO-05-80042

    Aurora, Colorado

  • Biomed Testing Facility #BIO-06-60612

    Chicago, Illinois

  • Maryland Locations Biomed Testing Facility #BIO-7-21205

    Baltimore, Maryland

  • Biomed Testing Facility #BIO-8-02115

    Boston, Massachusetts

  • Biomed Testing Facility #BIO-9-10467

    The Bronx, New York

  • Biomed Testing Facility #BIO-10-44195

    Cleveland, Ohio

  • Biomed Testing Facility #BIO-11-77030

    Houston, Texas

  • Biomed Testing Facility #BIO-12-98105

    Seattle, Washington

  • Biomed Research Unit-BIO-16-NSW

    Camperdown, New South Wales, Australia

  • Biomed Research Unit-BIO-15

    Sydney, New South Wales, Australia

  • Biomed Research Unit-BIO-13-VIC-3084 Heidelberg West, Victoria, Australia, 3084

    Heidelberg West, Victoria, Australia

  • Biomed Research Unit- BIO-14-VIC 3010

    Parkville, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.